Cargando…

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population

Case series Patients: Female, 54-year-old • Female, 67-year-old • Female, 58-year-old • Female, 63-year-old • Female, 61-year-old • Female, 60-year-old • Female, 63-year-old • Female, 60-year-old • Female, 40-year-old Final Diagnosis: Invasive lobular carcinoma HER-2/neu-positive Symptoms: Breast lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osmani, Asif Husain, Tulbah, Asma M., Alsayed, Adher, AlShanqeeti, Ali, Al-Twegieri, Taher, Ajarim, Dahish S., Suleman, Kausar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872945/ https://www.ncbi.nlm.nih.gov/pubmed/33544698 http://dx.doi.org/10.12659/AJCR.928012

Ejemplares similares

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
por: Ghebeh, Hazem, et al.
Publicado: (2021)

Behavior and Outcomes of Pregnancy Associated Breast Cancer
por: Suleman, Kausar, et al.
Publicado: (2019)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

Association Between Obesity and Clinicopathological Profile of Patients with Newly Diagnosed Non-Metastatic Breast Cancer in Saudi Arabia
por: Alshamsan, Bader, et al.
Publicado: (2022)

Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience
por: Elkum, Naser, et al.
Publicado: (2007)

Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
por: Al-Tweigeri, Taher, et al.
Publicado: (2021)

Fascin Is a Key Regulator of Breast Cancer Invasion That Acts via the Modification of Metastasis-Associated Molecules
por: Al-Alwan, Monther, et al.
Publicado: (2011)

Obesity is a significant risk factor for breast cancer in Arab women
por: Elkum, Naser, et al.
Publicado: (2014)

Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis
por: Qattan, Amal, et al.
Publicado: (2021)

Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination
por: Al Sayed, Adher D., et al.
Publicado: (2019)

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment
por: Siraj, Abdul Khalid, et al.
Publicado: (2018)

Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis
por: Bu, Rong, et al.
Publicado: (2016)

High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer
por: Siraj, Abdul K, et al.
Publicado: (2021)

ALK alteration is a frequent event in aggressive breast cancers
por: Siraj, Abdul K., et al.
Publicado: (2015)

FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer
por: Siraj, Abdul Khalid, et al.
Publicado: (2018)

PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2021)

Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women
por: Colak, Dilek, et al.
Publicado: (2013)

Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
por: Siraj, Abdul Khalid, et al.
Publicado: (2021)

Knowledge and Practice of COVID-19 Infection Control Among Dental Students and Interns: A Cross-Sectional Survey
por: Bin Mubayrik, Azizah, et al.
Publicado: (2021)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Towards safety of oral anti-cancer agents, the need to educate our pharmacists
por: Mekdad, Sanaa Saeed, et al.
Publicado: (2017)

Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country
por: Shabbir, Asma, et al.
Publicado: (2016)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
por: Woo, Jennifer S., et al.
Publicado: (2016)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type
por: Nelson, Blessie, et al.
Publicado: (2020)

PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients
por: Siraj, Abdul K., et al.
Publicado: (2023)

Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer
por: Qattan, Amal, et al.
Publicado: (2022)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Successful outcome of Langerhans cell histiocytosis complicated by therapy-related myelodysplasia and acute myeloid leukemia: a case report
por: Al-Anazi, Khalid A, et al.
Publicado: (2008)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ou41pmre2nq17b3onefacd2b2s